Rate Benchmarking
Compare your rates with similar providers.
Select a published rate, define comparable providers, and see where that rate falls in your market.
See a sample rate comparisonHCPCS J0695 is classified under Drugs Administered Other than Oral Method, in the Drugs, Administered by Injection subgroup.
| Key Fact | Detail |
|---|---|
| Service Type | Drugs Administered Other than Oral Method Drugs, Administered by Injection |
| Common Place of Service | 99Other POS |
| Hospital Outpatient Group (APC) | APC 9452 - Inj ceftolozane tazobactam |
| Surgery Center Payment (ASC) | K2 - Drug paid separately with a covered surgery, at the OPPS rate |
| Common Revenue Codes | 06360250 |
| Medicare Fee Schedule | $10.02 per billing unit (October 2026 ASP)View Medicare rates for J0695 |
| Medicaid Fee Schedule | $9.32 median of the 8 states in the free previewView Medicaid rates for J0695 |
| Medicare Payment Limit | |
| WAC Price | Lorem ipsum dolor sit amet consectetur Lorem ipsum dolor sit amet consectetur VisitBuyandBill.com |
| Related NDC Codes | • 67919003001 - ZERBAXA (ceftolozane and tazobactam), injection, powder, lyophilized, for solution |
National average reimbursement for HCPCS J0695 by major payers:

$8.54
BCBS / Anthem

$8.41
UnitedHealthcare

$8.86
Aetna

$8.69
Cigna
Choose a payer to see a sample of rates for HCPCS J0695.
Ganana Tesfa
Medhealth
Nilanjana Dasgupta
Central Texas Hospitalists, P.A.
Texas Partners Healthcare Group, PA
Texas Partners Healthcare Group PA
Podiatric Medical Partners Of Texas, PA
Podiatric Medical Partners Of
Medical Arts Internal Medicine, P.A.
Medical Arts Internal Medicine P.A.
Choose your state and specialty to build a report from payer-published rates.
Looking for other data?
Rate Benchmarking
Select a published rate, define comparable providers, and see where that rate falls in your market.
See a sample rate comparisonPayer Contract Negotiation
Use your fee schedule and market benchmarks to set target rates and draft a letter for your payer.
See a sample payer proposalHCPCS J0695 vs. Other Drugs, Administered by Injection Codes
The table lists codes related to J0695. Select one to see its fee schedule.
| Code | Description |
|---|---|
| 67919003001-NDC | ZERBAXA (ceftolozane and tazobactam), injection, powder, lyophilized, for solution |
| J0694-HCPCS | Injection, cefoxitin sodium, 1 gm |
| J0695-HCPCS | Injection, ceftolozane 50 mg and tazobactam 25 mg |
| J0696-HCPCS | Injection, ceftriaxone sodium, per 250 mg |
What is a fee schedule?
A fee schedule is a list of fixed prices that healthcare providers charge for specific services, including HCPCS J0695. These prices vary depending on payer type (Medicare, Medicaid, private insurance), geographic location, and provider contracts.
Understanding the J0695 fee schedule helps patients estimate costs and providers optimize billing for accurate reimbursements.
Factors that affect fee schedules
Medicare & Medicaid Rates
Government-set reimbursement amounts
Private Insurance Rates
Negotiated rates between providers and insurance companies
Geographic Location
Costs may be higher in urban areas.
Provider Type
Hospital providers may have different rates than private practice.
Bring your top codes (like HCPCS J0695) and we'll show you how you compare in 15 minutes or less.
Medicare's hospital outpatient payment system (OPPS) assigns HCPCS J0695 to APC 9452 (Inj ceftolozane tazobactam). An APC groups outpatient services that Medicare pays at the same base rate.
CMS lists HCPCS J0695 with ASC payment indicator K2: Drug paid separately with a covered surgery, at the OPPS rate.
Hospital price transparency files list HCPCS J0695 under these revenue codes: 0636 and 0250. A revenue code names the hospital department or charge category for the line; it does not change what the service is.